Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Share:

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2019MaintainsOverweight
Oct 2019ReinstatesNeutral
Aug 2019Initiates Coverage OnOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CYCowen & Co.Downgrades
CNPCredit SuisseDowngrades28.0
CNPGuggenheim SecuritiesDowngrades29.0
BRKRStifel NicolausInitiates Coverage On53.0
AWKJP MorganInitiates Coverage On127.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Six Stocks That Held Their 50-Day Moving Average Last Week

Benzinga's Volume Movers